Colon and rectum (Neoplasia)

LE WE PMID CA

Colon and rectum (Neoplasia)

1479

Kolon und Rektum (Neubildung)

5 Aminosalicylate

5T4 Oncotrophoblast glycoprotein

Anus (Neoplasm)

ATP5A1

Bevacizumab ttVEGF

BRAF

Capecitabine

Cell stress (BASKET)

Cetuximab ttEGFR

Chemoprevention

Cholic acid

Chromoendoscopy

Colon and rectum (aberrant crypt foci)

Colon and rectum (CT)

Colon and rectum (Neoplasia)

Colon and rectum (Polyp)

CpG island

CRAC

Epithelio mesenchymal transition

ERG transcription factor

ERS UFR (Toxikologie)

Genetic instability

Genetics (Microsatellite)

Inflammatory bowel diseases

Interleukin17

Irinotecan

JC Virus

Kidney (Neoplasia RCC)

KRAS

Lynch syndrome

Mammary gland (Neoplasia)

Medical ethics

MLH1

MSH2

MSH6

MTUS1

MUTYH

MYH

Neoplasia (Carcinogenesis)

Neoplasia (Inherited)

Neoplasia (Invasion and metastasis)

Neoplasia (Tumor biology and immunology)

Neoplasia (Tumor markers)

Neuroendocrine System (Neoplasia Carcinoid)

Notch

Optical imaging (Instrumentation)

Oxaliplatin

Panitumomab ttEGFR

PI3KC3

PMS2

Prostate (Neoplasia)

Raltitrexed

Receptor (PPAR gamma)

RNA (MicroRNA)

S100A4

SEPT9

TGF beta

Tivozanib ttVEGF

UFT

UGT1A1

Ursodeoxycholic acid

Vaccine (Oncology)

Wnt beta Catenin TCF

1988 1	Dukes' classification of rectal cancer. [3279538] South Med J 81(3): 407-8 (1988)
2003 2	Colorectal polyps. [15931318] Clin Med Res 1(3): 261-2 (2003)
2005 3	Hereditary non-polyposis colon cancer. [16025587] Ulster Med J 74(1): 14-21 (2005)
1992 4	Familial adenomatous polyposis. [1311383] J R Soc Med 85(2): 63-5 (1992)
2010 5	The differential diagnosis and surveillance of hereditary gastrointestinal polyposis syndromes. [20358032] Dtsch Arztebl Int 107(10): 163-73 (2010)
2009 6	Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. [20062582] Dtsch Arztebl Int 106(51-52): 843-8 (2009)
2007 7	A review of the role of capecitabine in the treatment of colorectal cancer. [18488072] Ther Clin Risk Manag 3(3): 421-31 (2007)
2008 8	The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. [18462574] Health Technol Assess 12(15): iii-ix, xi-162 (2008)
2007 9	Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. [17346499] Health Technol Assess 11(12): 1-128, iii-iv (2007)
2006 10	Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation. [17083853] Health Technol Assess 10(45): 1-141, iii-iv (2006)
2006 11	The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. [17049138] Health Technol Assess 10(41): iii-iv, xi-xiv, 1-185 (2006)
2010 12	Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. [21042543] Core Evid 5(-): 61-76 (2010)
2008 13	Extracolonic manifestations of hereditary colorectal cancer syndromes. [20011437] Clin Colon Rectal Surg 21(4): 263-72 (2008)
2009 14	Early detection of and screening for colorectal neoplasia. [20431727] Gut Liver 3(2): 69-80 (2009)
2008 15	Noninvasive molecular biomarkers for the detection of colorectal cancer. [18959813] BMB Rep 41(10): 685-92 (2008)
2006 16	Induction chemoradiation for rectal cancer. [17178968] Arch Surg 141(12): 1246-52; discussion 1253 (2006)
1999 17	Colorectal cancer in adolescents. [10364965] Ann R Coll Surg Engl 81(2): 100-4 (1999)
1995 18	Colorectal cancer: surgical prophylaxis and chemoprevention. [7486766] Ann R Coll Surg Engl 77(5): 372-6 (1995)
1995 19	Adjuvant chemotherapy for colorectal cancer. [7793820] Ann R Coll Surg Engl 77(2): 81-4 (1995)
2004 20	Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients. [15273550] Ann Surg 240(2): 260-8 (2004)
2002 21	Long-term results of local excision for rectal cancer. [12368681] Ann Surg 236(4): 522-29; discussion 529-30 (2002)
2001 22	Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. [11371736] Ann Surg 233(6): 778-85 (2001)
2001 23	Comparison of quality of life in patients undergoing abdominoperineal extirpation or anterior resection for rectal cancer. [11176119] Ann Surg 233(2): 157-8 (2001)
1998 24	Periampullary adenocarcinoma: analysis of 5-year survivors. [9637545] Ann Surg 227(6): 821-31 (1998)
1998 25	Surgical treatment of adenocarcinoma of the rectum. [9637543] Ann Surg 227(6): 800-11 (1998)
1995 26	Clinical behavior and prognostic factors of periampullary adenocarcinoma. [7487210] Ann Surg 222(5): 632-7 (1995)
1989 27	Sphincter-saving procedures for distal carcinoma of the rectum. [2642688] Ann Surg 209(1): 1-18 (1989)
1988 28	Is total pelvic exenteration reasonable primary treatment for rectal carcinoma? [3291792] Ann Surg 207(6): 670-8 (1988)
1966 29	Carcinoma of the distal large bowel: 32-year review of 1,026 cases. [5933798] Ann Surg 163(6): 838-49 (1966)
1966 30	Cancer of the colon, rectum and anus: review of 1,687 cases. [5933797] Ann Surg 163(6): 829-37 (1966)
2004 31	The evolution to stool DNA testing for colorectal cancer. [15191503] Aliment Pharmacol Ther 19(12): 1225-33 (2004)
2003 32	Review article: colorectal cancer chemotherapy. [14510741] Aliment Pharmacol Ther 18(7): 683-92 (2003)
2002 33	Review article: genetic testing and counselling for hereditary colorectal cancer. [12390093] Aliment Pharmacol Ther 16(11): 1843-57 (2002)
2001 34	Review article: non-systemic chemotherapy in the treatment of colorectal cancer-portal vein, hepatic arterial and intraperitoneal approaches. [11563991] Aliment Pharmacol Ther 15(10): 1527-41 (2001)
2008 35	Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. [19086328] Aliment Pharmacol Ther 28(3): 269-81 (2008)
2008 36	Review article: current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies. [18363897] Aliment Pharmacol Ther 27(11): 997-1005 (2008)
2007 37	Predictive and prognostic markers in colorectal cancer. [19262902] Gastrointest Cancer Res 1(6): 237-46 (2007)
2010 38	Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. [20383783] Target Oncol 5(1): 19-28 (2010)
2009 39	Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. [19915942] Target Oncol 4(4): 311-22 (2009)
2009 40	Microsatellite instability: a predictive marker in metastatic colorectal cancer? [19343302] Target Oncol 4(1): 57-62 (2009)
2008 41	UFT (tegafur-uracil) in rectal cancer. [18381370] Ann Oncol 19(8): 1371-8 (2008)
2008 42	Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. [18456760] Ann Oncol 19 Suppl 2(-): ii33-4 (2008)
2008 43	Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. [18456759] Ann Oncol 19 Suppl 2(-): ii31-2 (2008)
2008 44	Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. [18456758] Ann Oncol 19 Suppl 2(-): ii29-30 (2008)
2007 45	Integrative decisions in rectal cancer. [17631565] Ann Oncol 18 Suppl 9(-): ix127-31 (2007)
2007 46	The multidisciplinary treatment of rectal cancer: pathology. [17631564] Ann Oncol 18 Suppl 9(-): ix122-6 (2007)
2007 47	Multidisciplinary treatment of rectal cancer: medical oncology. [17631563] Ann Oncol 18 Suppl 9(-): ix114-21 (2007)
2007 48	Radiotherapy for localized rectal cancer. [17631562] Ann Oncol 18 Suppl 9(-): ix105-13 (2007)
2007 49	Cetuximab: clinical results in colorectal cancer. [17591840] Ann Oncol 18 Suppl 6(-): vi8-10 (2007)
2006 50	A multimodality approach to localized rectal cancer. [17018713] Ann Oncol 17 Suppl 10(-): x129-34 (2006)
2006 51	The integration of targeted agents into systemic therapy of metastatic colorectal cancer. [17018712] Ann Oncol 17 Suppl 10(-): x122-8 (2006)
2006 52	Adjuvant therapy in colon cancer--what, when and how? [16524974] Ann Oncol 17(9): 1347-59 (2006)
2006 53	Alternative clinical end points in rectal cancer--are we getting closer? [16873440] Ann Oncol 17(8): 1239-48 (2006)
2005 54	Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. [15870084] Ann Oncol 16(8): 1311-9 (2005)
2005 55	(Neo-)adjuvant treatments in colorectal cancer. [15958444] Ann Oncol 16 Suppl 2(-): ii133-40 (2005)
2004 56	Importance of microsatellite instability (MSI) in colorectal cancer: MSI as a diagnostic tool. [15477322] Ann Oncol 15 Suppl 4(-): iv283-4 (2004)
2002 57	Molecular and biochemical markers in colorectal cancer. [12401696] Ann Oncol 13 Suppl 4(-): 235-45 (2002)
2001 58	Microsatellite instability: application in hereditary non-polyposis colorectal cancer. [11300317] Ann Oncol 12(2): 151-60 (2001)
2007 59	Adjuvant treatment of colorectal cancer. [17507442] CA Cancer J Clin 57(3): 168-85 (2007)
1997 60	Surgical treatment of colorectal cancer. [9074489] CA Cancer J Clin 47(2): 113-28 (1997)
1997 61	Diagnosing colorectal carcinoma: clinical and molecular approaches. [9074487] CA Cancer J Clin 47(2): 70-92 (1997)
2008 62	Systemic therapy for metastatic colorectal cancer: current questions. [18338815] Cancer 112(9): 1879-91 (2008)
2008 63	Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer. [18008365] Cancer 112(1): 50-4 (2008)
2007 64	Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. [17671985] Cancer 110(5): 980-8 (2007)
2005 65	Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. [15880563] Cancer 103(12): 2435-46 (2005)
2004 66	Adjuvant postoperative radiotherapy for colon carcinoma. [15316945] Cancer 101(6): 1338-44 (2004)
2004 67	New systemic frontline treatment for metastatic colorectal carcinoma. [15073842] Cancer 100(8): 1558-77 (2004)
2010 68	Radiation therapy for rectal cancer: current status and future directions. [20010516] Cancer Control 17(1): 25-34 (2010)
2010 69	An update on laparoscopic resection for rectal cancer. [20010515] Cancer Control 17(1): 16-24 (2010)
2010 70	Current progress in targeted therapy for colorectal cancer. [20010514] Cancer Control 17(1): 7-15 (2010)
2003 71	Methods and results of sphincter-preserving surgery for rectal cancer. [12794619] Cancer Control 10(3): 212-8 (2003)
2003 72	The role of total mesorectal excision in the management of rectal cancer. [12794618] Cancer Control 10(3): 205-11 (2003)
2008 73	U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. [18316547] Clin Cancer Res 14(5): 1296-302 (2008)
2007 74	Radiation therapy in stage II and III rectal cancer. [18006798] Clin Cancer Res 13(22 Pt 2): 6903s-8s (2007)
2007 75	Multidisciplinary management of patients with advanced rectal cancer. [18006795] Clin Cancer Res 13(22 Pt 2): 6890s-3s (2007)
2007 76	Management of early rectal T1 and T2 cancers. [18006794] Clin Cancer Res 13(22 Pt 2): 6885s-9s (2007)
2007 77	Optimal methods for staging rectal cancer. [18006793] Clin Cancer Res 13(22 Pt 2): 6877s-84s (2007)
2007 78	Newer pathologic assessment techniques for colorectal carcinoma. [18006792] Clin Cancer Res 13(22 Pt 2): 6871s-6s (2007)
2007 79	Optimal pathologic staging: defining stage II disease. [18006791] Clin Cancer Res 13(22 Pt 2): 6862s-70s (2007)
2009 80	FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. [19282350] Oncologist 14(3): 284-90 (2009)
2007 81	Locally advanced rectal cancer: what is the evidence for induction chemoradiation? [18055850] Oncologist 12(11): 1309-18 (2007)
2006 82	Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer. [17030644] Oncologist 11(9): 1018-24 (2006)
2005 83	Critical evaluation of current treatments in metastatic colorectal cancer. [15821245] Oncologist 10(4): 250-61 (2005)
2006 84	EphB/EphrinB receptors and Wnt signaling in colorectal cancer. [16397205] Cancer Res 66(1): 2-5 (2006)
2006 85	Serrated pathway and APC (conventional)-type colorectal polyps: molecular-morphologic correlations, genetic pathways, and implications for classification. [16483003] Am J Clin Pathol 125(1): 146-53 (2006)
2005 86	Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. [16191506] Am J Clin Pathol 124(3): 380-91 (2005)
2003 87	Hyperplastic-like colon polyps that preceded microsatellite-unstable adenocarcinomas. [12817424] Am J Clin Pathol 119(6): 778-96 (2003)
2003 88	Hyperplastic-like polyps as precursors of microsatellite-unstable colorectal cancer. [12817423] Am J Clin Pathol 119(6): 773-5 (2003)
2002 89	Beta-catenin--a linchpin in colorectal carcinogenesis? [11839557] Am J Pathol 160(2): 389-401 (2002)
1994 90	Colon cancer connections. Cancer syndrome meets molecular biology meets histopathology. [8030741] Am J Pathol 145(1): 1-6 (1994)
2008 91	Guidelines for surveillance intervals after polypectomy: coping with the evidence. [18347353] Ann Intern Med 148(6): 477-9 (2008)
2008 92	Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years. [18347350] Ann Intern Med 148(6): 419-26 (2008)
2003 93	The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. [12667026] Ann Intern Med 138(7): 560-70 (2003)
2001 94	Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. [11601929] Ann Intern Med 135(8 Pt 1): 577-88 (2001)
2001 95	Bethesda guidelines: relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer. [11601928] Ann Intern Med 135(8 Pt 1): 566-76 (2001)
1995 96	Prevention of colorectal cancer by endoscopic polypectomy. [7486491] Ann Intern Med 123(12): 949-50 (1995)
1993 97	Polyp guideline: diagnosis, treatment, and surveillance for patients with nonfamilial colorectal polyps. The Practice Parameters Committee of the American College of Gastroenterology. [8379605] Ann Intern Med 119(8): 836-43 (1993)
1963 98	COLON AND RECTAL POLYPS. RELATIONSHIP TO CARCINOMA. [14084684] Calif Med 99(-): 378-81 (1963)
2005 99	Chemoradiotherapy for colorectal cancer. [16009693] Gut 54(8): 1194-202 (2005)
2005 100	Adherence to BSG adenoma surveillance guidelines will reduce colonoscopic workload. [15591532] Gut 54(1): 173 (2005)
2004 101	An update on the genetics of colorectal cancer. [15358723] Hum Mol Genet 13 Spec No 2(-): R177-85 (2004)
2001 102	Deficient DNA mismatch repair: a common etiologic factor for colon cancer. [11257106] Hum Mol Genet 10(7): 735-40 (2001)
2004 103	My approach to serrated polyps of the colorectum. [15220357] J Clin Pathol 57(7): 682-6 (2004)
2008 104	Molecular classification and correlates in colorectal cancer. [18165277] J Mol Diagn 10(1): 13-27 (2008)
2005 105	Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. [15855432] JAMA 293(16): 1986-94 (2005)
2003 106	Colorectal carcinoma: diagnostic, prognostic, and molecular features. [12692203] Mod Pathol 16(4): 376-88 (2003)
2003 107	Gastrointestinal inherited polyposis syndromes. [12692201] Mod Pathol 16(4): 359-65 (2003)
1983 108	Familial colonic cancer syndromes. [6356610] West J Med 139(3): 351-9 (1983)
2009 109	Efficacy of the revised Vienna Classification for diagnosing colorectal epithelial neoplasias. [19452577] World J Gastroenterol 15(19): 2351-6 (2009)
2006 110	Complementary analysis of microsatellite tumor profile and mismatch repair defects in colorectal carcinomas. [17009390] World J Gastroenterol 12(37): 5932-40 (2006)
2003 111	Aberrant crypt foci as microscopic precursors of colorectal cancer. [14669304] World J Gastroenterol 9(12): 2642-9 (2003)
2008 112	Surgical treatment for rectal cancer: an international perspective on what the medical gastroenterologist needs to know. [18528924] World J Gastroenterol 14(21): 3281-9 (2008)
2007 113	Rectal cancer treatment: improving the picture. [17990346] World J Gastroenterol 13(44): 5805-12 (2007)
2006 114	Modern management of rectal cancer: a 2006 update. [16718838] World J Gastroenterol 12(20): 3186-95 (2006)
2007 115	The genetics of hereditary colon cancer. [17938238] Genes Dev 21(20): 2525-38 (2007)
2007 116	Flat colorectal neoplasms: definition, importance, and visualization on CT colonography. [17377029] AJR Am J Roentgenol 188(4): 953-9 (2007)
1993 117	Colonic submucosal tumors: a new classification based on radiologic characteristics. [8424341] AJR Am J Roentgenol 160(2): 315-20 (1993)
1991 118	Colorectal cancer: cross-sectional imaging for staging of primary tumor and detection of local recurrence. [2017950] AJR Am J Roentgenol 156(5): 909-15 (1991)
2007 119	Evaluation of submucosal lesions of the large intestine: part 1. Neoplasms. [18025511] Radiographics 27(6): 1681-92 (2007)
2002 120	Differential diagnosis of periampullary carcinomas at MR imaging. [12432106] Radiographics 22(6): 1335-52 (2002)
1995 121	From the archives of the AFIP. Colorectal adenocarcinoma: radiologic-pathologic correlation. [7899592] Radiographics 15(1): 127-46; quiz 148-9 (1995)
2010 122	Restaging of Rectal Cancer with MR Imaging after Concurrent Chemotherapy and Radiation Therapy. [20228331] Radiographics 30(2): 503-16 (2010)
2004 123	Rectal cancer: review with emphasis on MR imaging. [15286305] Radiology 232(2): 335-46 (2004)
2000 124	Diagnosis of colorectal neoplasms at double-contrast barium enema examination. [10887222] Radiology 216(1): 11-8 (2000)
2011 125	Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. [21779535] Am J Cancer Res 1(5): 650-62 (2011)
2010 126	Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. [20219759] Ann Oncol 21(8): 1579-84 (2010)
2010 127	Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. [20555107] Ann Oncol 21 Suppl 5(-): v70-7 (2010)
2010 128	Familial colorectal cancer risk: ESMO Clinical Practice Guidelines. [20555108] Ann Oncol 21 Suppl 5(-): v78-81 (2010)
2010 129	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. [20555109] Ann Oncol 21 Suppl 5(-): v82-6 (2010)
2010 130	Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. [20555112] Ann Oncol 21 Suppl 5(-): v93-7 (2010)
2010 131	What can the molecular pathologist offer for optimal decision making? [20943604] Ann Oncol 21 Suppl 7(-): vii123-9 (2010)
2010 132	Chemotherapy: which drug and when? [20943605] Ann Oncol 21 Suppl 7(-): vii130-3 (2010)
2010 133	How to integrate molecular targeted agents in the continuum of care. [20943606] Ann Oncol 21 Suppl 7(-): vii134-9 (2010)
2005 134	Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. [15923428] Ann Oncol 16 Suppl 4(-): iv44-49 (2005)
2009 135	Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. [19454461] Ann Oncol 20 Suppl 4(-): 49-50 (2009)
2009 136	Familial colorectal cancer risk: ESMO clinical recommendations. [19454462] Ann Oncol 20 Suppl 4(-): 51-3 (2009)
2009 137	Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. [19454463] Ann Oncol 20 Suppl 4(-): 54-6 (2009)
2009 138	Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. [19454465] Ann Oncol 20 Suppl 4(-): 61-3 (2009)
2010 139	KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. [19936839] Ann Surg Oncol 17(4): 1168-76 (2010)
2008 140	MRI for detection of extramural vascular invasion in rectal cancer. [18941094] AJR Am J Roentgenol 191(5): 1517-22 (2008)
2009 141	Advances in the treatment of metastatic colorectal cancer. [19955859] Am J Ther 16(5): 412-20 (2009)
2010 142	Prevalence and predictors of appropriate colorectal cancer surveillance in Lynch syndrome. [20354509] Am J Gastroenterol 105(8): 1851-60 (2010)
2010 143	MicroRNAs as biomarkers in colorectal cancer. [20829435] Am J Pathol 177(4): 1592-9 (2010)
2011 144	Lynch syndrome screening implementation: business analysis by a healthcare system. [21851136] Am J Manag Care 17(8): e288-300 (2011)
2010 145	Colorectal cancer screening: the role of CT colonography. [20731011] World J Gastroenterol 16(32): 3987-94 (2010)
2011 146	Multifaceted nature of membrane microdomains in colorectal cancer. [21390137] World J Gastroenterol 17(6): 681-90 (2011)
2011 147	Identification of patients at-risk for Lynch syndrome in a hospital-based colorectal surgery clinic. [21390147] World J Gastroenterol 17(6): 766-73 (2011)
2011 148	Management of stage IV rectal cancer: palliative options. [21412493] World J Gastroenterol 17(7): 835-47 (2011)
2011 149	Neoadjuvant vs adjuvant pelvic radiotherapy for locally advanced rectal cancer: Which is superior? [21412494] World J Gastroenterol 17(7): 848-54 (2011)
2011 150	Sphincter preservation for distal rectal cancer--a goal worth achieving at all costs? [21412495] World J Gastroenterol 17(7): 855-61 (2011)
2011 151	Isolated lymphoid follicles in colon: switch points between inflammation and colorectal cancer? [21483625] World J Gastroenterol 17(13): 1666-73 (2011)
2011 152	Patterns of local recurrence in rectal cancer after a multidisciplinary approach. [21483626] World J Gastroenterol 17(13): 1674-84 (2011)
2010 153	Surveillance for colitis-associated colon neoplasia. [20872964] World J Gastroenterol 16(37): 4646-51 (2010)
2007 154	Diagnostic procedures for submucosal tumors in the gastrointestinal tract. [17659668] World J Gastroenterol 13(24): 3301-10 (2007)
2007 155	Therapeutic procedures for submucosal tumors in the gastrointestinal tract. [17659670] World J Gastroenterol 13(24): 3316-22 (2007)
2007 156	Serrated neoplasia of the colorectum. [17657832] World J Gastroenterol 13(28): 3792-8 (2007)
2007 157	Adjuvant therapies for colorectal cancer. [17657833] World J Gastroenterol 13(28): 3799-805 (2007)
2007 158	Metastatic colorectal cancer-past, progress and future. [17657834] World J Gastroenterol 13(28): 3806-15 (2007)
2007 159	Combining chemotherapy and targeted therapies in metastatic colorectal cancer. [17990352] World J Gastroenterol 13(44): 5867-76 (2007)
2007 160	Colorectal cancer. [17285793] Mayo Clin Proc 82(1): 114-29 (2007)
2011 161	Genetics, cytogenetics, and epigenetics of colorectal cancer. [21490705] J Biomed Biotechnol 2011(-): 792362 (2011)
2011 162	Epithelial tight junctional changes in colorectal cancer tissues. [21479352] ScientificWorldJournal 11(-): 826-41 (2011)
2011 163	Molecular imaging using positron emission tomography in colorectal cancer. [21616042] Discov Med 11(60): 435-47 (2011)
2011 164	The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. [21356164] Discov Med 11(57): 95-105 (2011)
2010 165	New strategies for treatment of KRAS mutant metastatic colorectal cancer. [20460490] Clin Cancer Res 16(11): 2921-6 (2010)
2010 166	A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. [20584808] Oncologist 15(7): 699-731 (2010)
2010 167	Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. [20133499] Oncologist 15(2): 157-67 (2010)
2006 168	Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. [16770784] Cancer 107(2): 221-31 (2006)
2005 169	P53 abnormalities and outcomes in colorectal cancer: a systematic review. [15668707] Br J Cancer 92(3): 434-44 (2005)
2009 170	Molecular origins of cancer: Molecular basis of colorectal cancer. [20018966] N Engl J Med 361(25): 2449-60 (2009)
2003 171	Hereditary colorectal cancer. [12621137] N Engl J Med 348(10): 919-32 (2003)
2010 172	The origins of colorectal carcinoma: specific nomenclature for different pathways and precursor lesions. [21085545] Dtsch Arztebl Int 107(43): 760-6 (2010)
2006 173	How can we best detect hereditary non-polyposis colorectal cancer? [16515428] Med J Aust 184(5): 206-7 (2006)
2010 174	Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer. [21047491] Health Technol Assess 14(Suppl. 2): 47-53 (2010)
2010 175	Cetuximab for the first-line treatment of metastatic colorectal cancer. [20507797] Health Technol Assess 14 Suppl 1(-): 1-8 (2010)
2010 176	Kras in metastatic colorectal cancer. [21104470] Swiss Med Wkly 140(-): w13112 (2010)
2010 177	Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis. [21163137] Chin Med J (Engl) 123(22): 3314-8 (2010)
2006 178	Rectal cancer. [17151562] Gastroenterol Clin Biol 30 Spec No 2(-): 2S43-2S51 (2006)
2006 179	Metastatic colorectal cancer. [17151561] Gastroenterol Clin Biol 30 Spec No 2(-): 2S30-2S42 (2006)
2006 180	Colon cancer. [17151560] Gastroenterol Clin Biol 30 Spec No 2(-): 2S24-2S29 (2006)
2010 181	Ursodeoxycholic acid and chemoprevention of colorectal cancer. [20609543] Gastroenterol Clin Biol 34(10): 516-22 (2010)
2011 182	Fecal occult blood testing while waiting for screening colonoscopy in average-risk individuals: durable option or short-term solution? [21647456] Can J Gastroenterol 25(5): 247 (2011)
2003 183	Elastofibromatous polyp of the sigmoid colon--a case report and review of gastrointestinal elastofibromas. [12704473] Can J Gastroenterol 17(4): 275-7 (2003)
2007 184	Colorectal cancer: imaging surveillance following resection of primary tumour. [17921088] Cancer Imaging 7 Spec No A(-): S143-9 (2007)
2011 185	Strategies in screening for colon carcinoma. [21444935] Neth J Med 69(3): 112-9 (2011)
2005 186	Targeted therapies in the treatment of colorectal cancers. [15855893] Cancer Control 12(2): 105-10 (2005)
2005 187	Genomic instability and colorectal cancer. [16351460] Rev Esp Enferm Dig 97(10): 683-7 (2005)
2005 188	Hereditary nonpolyposis colorectal cancer identification and surveillance of high-risk families. [15962087] Clinics (Sao Paulo) 60(3): 251-6 (2005)
2010 189	Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. [21317460] Oncotarget 1(7): 651-61 (2010)
2007 190	Epidemiology of colonic aberrant crypt foci: review and analysis of existing studies. [17182176] Cancer Lett 252(2): 171-83 (2007)
2008 191	Pro-inflammatory prostaglandins and progression of colorectal cancer. [18406516] Cancer Lett 267(2): 197-203 (2008)
2009 192	Should computed tomographic colonography replace optical colonoscopy in screening for colorectal cancer? [19413183] Pol Arch Med Wewn 119(4): 236-41 (2009)
2009 193	Role of Notch signaling in colorectal cancer. [19793799] Carcinogenesis 30(12): 1979-86 (2009)
2008 194	Updating the management of rectal cancer. [18392247] J Gastrointestin Liver Dis 17(1): 69-74 (2008)
2008 195	Hydrophobic bile acids, genomic instability, Darwinian selection, and colon carcinogenesis. [21677822] Clin Exp Gastroenterol 1(): 19-47 (2008)
2010 196	JC virus in the pathogenesis of colorectal cancer, an etiological agent or another component in a multistep process? [20167111] Virol J 7(-): 42 (2010)
2008 197	K-Ras mutation status as a predictive biomarker in metastatic colorectal cancer. [20477429] Biomark Med 2(2): 97-9 (2008)
2010 198	Role of transforming growth factor-β in inflammatory bowel disease and colitis-associated colon cancer. [20848467] Inflamm Bowel Dis 16(11): 1963-8 (2010)
2007 199	Role of chromoendoscopy in colon cancer surveillance in inflammatory bowel disease. [17309075] Inflamm Bowel Dis 13(7): 911-7 (2007)
2009 200	Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. [18942763] Inflamm Bowel Dis 15(4): 630-8 (2009)
2008 201	Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. [17932965] Inflamm Bowel Dis 14(2): 265-74 (2008)
2007 202	The canonical Wnt signalling pathway and its APC partner in colon cancer development. [16840506] Gut 56(3): 417-25 (2007)
2010 203	Hereditary and familial colon cancer. [20420945] Gastroenterology 138(6): 2044-58 (2010)
2010 204	Primary prevention of colorectal cancer. [20420944] Gastroenterology 138(6): 2029-2043.e10 (2010)
2010 205	Optical molecular imaging approaches in colorectal cancer. [20026448] Gastroenterology 138(2): 419-22 (2010)
2008 206	Genomic and epigenetic instability in colorectal cancer pathogenesis. [18773902] Gastroenterology 135(4): 1079-99 (2008)
2008 207	Systemic treatment of colorectal cancer. [18471507] Gastroenterology 134(5): 1296-310 (2008)
2011 208	Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer. [21874108] Curr Oncol 18(4): e180-4 (2011)
2009 209	Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. [19386128] J Hematol Oncol 2(-): 18 (2009)
2008 210	Nomenclature, molecular genetics and clinical significance of the precursor lesions in the serrated polyp pathway of colorectal carcinoma. [18787610] Int J Clin Exp Pathol 1(4): 317-24 (2008)
2009 211	How much does colonoscopy reduce colon cancer mortality? [19075200] Ann Intern Med 150(1): 50-2 (2009)
2007 212	Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. [17764220] Evid Rep Technol Assess (Full Rep) -(150): 1-180 (2007)
2011 213	Mouse models of colorectal cancer. [21718591] Chin J Cancer 30(7): 450-62 (2011)
2011 214	Capecitabine in the management of colorectal cancer. [21629830] Cancer Manag Res 3(-): 79-89 (2011)
2011 215	Preventing bowel cancer: an insight for clinicians. [22084641] Ther Adv Med Oncol 3(6): 269-77 (2011)
2007 216	Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care. [21221177] Core Evid 2(2): 81-8 (2007)
2011 217	CpG island methylation in colorectal cancer: past, present and future. [21559209] Patholog Res Int 2011(-): 902674 (2011)
2011 218	Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. [21773077] World J Clin Oncol 2(6): 272-80 (2011)
2008 219	Polyp surveillance. [20011434] Clin Colon Rectal Surg 21(4): 237-46 (2008)
2009 220	Overview of systemic therapy for colorectal cancer. [21037816] Clin Colon Rectal Surg 22(4): 251-6 (2009)
2009 221	Surveillance after curative resection of colorectal cancer. [21037815] Clin Colon Rectal Surg 22(4): 242-50 (2009)
2009 222	Screening options and recommendations for colorectal cancer. [21037811] Clin Colon Rectal Surg 22(4): 209-17 (2009)
2007 223	Recently identified colon cancer predispositions: MYH and MSH6 mutations. [17920897] Semin Oncol 34(5): 418-24 (2007)
2010 224	Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond. [20932136] Expert Rev Gastroenterol Hepatol 4(5): 525-9 (2010)
2011 225	Emerging role of vitamin D in colorectal cancer. [22007275] World J Gastrointest Oncol 3(8): 123-7 (2011)
2010 226	Peroxisome proliferator-activated receptor γ and colorectal cancer. [21160824] World J Gastrointest Oncol 2(3): 159-64 (2010)
2002 227	Colorectal cancer: targeting metastasis and angiogenesis. [12450417] Clin Colorectal Cancer 1(4): 200 (2002)
2002 228	Matrix metalloproteinases in colorectal cancer. [12450419] Clin Colorectal Cancer 1(4): 208-19 (2002)
2008 229	Role of combined-modality therapy in the management of locally advanced rectal cancer. [19036689] Clin Colorectal Cancer 7(6): 369-75 (2008)
2008 230	Local excision for rectal carcinoma. [19036690] Clin Colorectal Cancer 7(6): 376-85 (2008)
2009 231	Colonic carcinoid tumors: a clinicopathologic study of 23 patients from a single institution. [20232008] Arq Gastroenterol 46(4): 288-93 (2009)
2010 232	Recent insights into the pathogenesis of colorectal cancer. [19786869] Curr Opin Gastroenterol 26(1): 47-52 (2010)
2010 233	Targeted imaging of flat and depressed colonic neoplasms. [20656254] Gastrointest Endosc Clin N Am 20(3): 579-83 (2010)
2009 234	Genetic testing for hereditary colorectal cancer. [19793575] Surg Oncol Clin N Am 18(4): 687-703 (2009)
2011 235	Clinical characteristics of colorectal carcinoid tumors. [21431092] J Korean Soc Coloproctol 27(1): 17-20 (2011)
2011 236	Current management of inflammatory bowel disease and colorectal cancer. [21673876] Gastrointest Cancer Res 4(2): 53-61 (2011)
2011 237	Wnt signaling and colon carcinogenesis: beyond APC. [21483657] J Carcinog 10(-): 5 (2011)
2010 238	JC virus infection: a cause of colorectal cancer? [20520564] J Clin Gastroenterol 44(7): 466-8 (2010)
2010 239	Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. [20587412] J Med Genet 47(9): 579-85 (2010)
2010 240	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. [20504361] J Exp Clin Cancer Res 29(-): 58 (2010)
2010 241	Gene dysregulations driven by somatic copy number aberrations-biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology. [20709793] J Mol Diagn 12(5): 552-61 (2010)
2010 242	Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. [20413677] J Mol Diagn 12(4): 433-40 (2010)
2011 243	An update on TroVax for the treatment of progressive castration-resistant prostate cancer. [21691576] Onco Targets Ther 4(-): 33-41 (2011)
2007 244	Blood markers for early detection of colorectal cancer: a systematic review. [17932341] Cancer Epidemiol Biomarkers Prev 16(10): 1935-53 (2007)
2009 245	Prospective study of JC virus seroreactivity and the development of colorectal cancers and adenomas. [19383887] Cancer Epidemiol Biomarkers Prev 18(5): 1515-23 (2009)
2009 246	Apoptosis in the colonic crypt, colorectal adenomata, and manipulation by chemoprevention. [19505899] Cancer Epidemiol Biomarkers Prev 18(6): 1680-7 (2009)
2009 247	Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. [19125126] Genet Med 11(1): 35-41 (2009)
2009 248	EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. [19125127] Genet Med 11(1): 42-65 (2009)
2009 249	Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. [19125129] Genet Med 11(1): 21-34 (2009)
2010 250	Colorectal cancer: molecular features and clinical opportunities. [20498827] Clin Biochem Rev 31(2): 31-8 (2010)
2009 251	Wnt up your mind - intervention strategies for S100A4-induced metastasis in colon cancer. [20093727] Gen Physiol Biophys 28 Spec No Focus(-): F55-64 (2009)
2011 252	Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. [21128987] Aliment Pharmacol Ther 33(3): 304-12 (2011)
2010 253	A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. [21063410] Br J Cancer 103(12): 1875-84 (2010)
2010 254	Cell surface markers in colorectal cancer prognosis. [21339979] Int J Mol Sci 12(1): 78-113 (2010)
PMC 255	Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). [24399885] Cancer Manag Res 5():377-85 (2013)
PMC 256	Interleukin-17: a promoter in colorectal cancer progression. [24382972] Clin Dev Immunol 2013():436307 (2013)
PMC 257	The molecular genetics of colorectal cancer. [24416503] Frontline Gastroenterol 5(1):26-30 (2014)
PMC 258	Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas. [22999960] Gastroenterology 144(1):53-5 (2013)
PMC 259	Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer. [24474830] Hosp Pharm 48(11):905-11 (2013)
PMC 260	Future directions for monitoring treatment response in colorectal cancer. [24396497] J Cancer 5(1):44-57 (2014)
PMC 261	Current approaches and challenges for monitoring treatment response in colon and rectal cancer. [24396496] J Cancer 5(1):31-43 (2014)
PMC 262	Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. [16295778] Korean J Intern Med 20(3):205-9 (2005)
PMC 263	Genomic instability in pre-neoplastic colonic lesions. [23396367] Oncogene 32(46):5331-2 (2013)
PMC 264	A study of genomic instability in early preneoplastic colonic lesions. [23246972] Oncogene 32(46):5333-7 (2013)
PMC 265	Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. [24400111] PLoS One 9(1):e84686 (2014)
PMC 266	Advances in radiotherapy and targeted therapies for rectal cancer. [24415852] World J Gastroenterol 20(1):1-5 (2014)
PMC 267	A second family with probable CRAC (colorectal adenomata and carcinoma) syndrome--a new familial cancer. [10595264] Dis Markers 15(1-3):120-2 (1999)
PMC 268	Treatment of lateral pelvic nodes metastases from rectal cancer: the future prospective. [24629807] G Chir 34(9-10):245-8 (2013)
PMC 269	Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. [23408352] Gut 63(2):317-25 (2014)
PMC 270	A gene expression and pre-mRNA splicing signature that marks the adenoma-adenocarcinoma progression in colorectal cancer. [24516561] PLoS One 9(2):e87761 (2014)
PMC 271	Field cancerization in the colon: a role for aberrant DNA methylation? [24760232] Gastroenterol Rep (Oxf) 2(1):16-20 (2014)
PMC 272	Re-evaluation of indications and outcomes of endoscopic excision procedures for colorectal tumors: a review. [24760234] Gastroenterol Rep (Oxf) 2(1):27-36 (2014)
PMC 273	Overview of single-port laparoscopic surgery for colorectal cancers: past, present, and the future. [24574772] World J Gastroenterol 20(4):997-1004 (2014)
PMC 274	Accumulation of aberrant DNA methylation during colorectal cancer development. [24574770] World J Gastroenterol 20(4):978-87 (2014)
PMC 275	Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer. [24574769] World J Gastroenterol 20(4):968-77 (2014)
PMC 276	Circulating and stool nucleic acid analysis for colorectal cancer diagnosis. [24574768] World J Gastroenterol 20(4):957-67 (2014)
PMC 277	Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. [24574767] World J Gastroenterol 20(4):943-56 (2014)
PMC 278	How to select the optimal treatment for first line metastatic colorectal cancer. [24574764] World J Gastroenterol 20(4):899-907 (2014)
PMC 279	Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled. [24574763] World J Gastroenterol 20(4):888-98 (2014)
PMC 280	Evolving treatment strategies for colorectal cancer: a critical review of current therapeutic options. [24574762] World J Gastroenterol 20(4):877-87 (2014)
PMC 281	Colorectal cancer disparities: issues, controversies and solutions. [24574761] World J Gastroenterol 20(4):869-76 (2014)
PMC 282	Intra-arterial therapies for metastatic colorectal cancer. [24436513] Semin Intervent Radiol 30(1):12-20 (2013)
PMC 283	Serrated pathway in colorectal carcinogenesis. [24627599] World J Gastroenterol 20(10):2634-40 (2014)
PMC 284	Interleukin-13 and its receptors in colorectal cancer (Review). [24649010] Biomed Rep 1(5):687-690 (2013)
PMC 285	Management of colorectal polyp cancers. [23131228] Ann R Coll Surg Engl 94(8):574-8 (2012)
PMC 286	Differential expression of carbohydrate antigen 19-9 in human colorectal cancer: A comparison with colon and rectal cancers. [24649295] Mol Clin Oncol 1(6):1072-1078 (2013)
PMC 287	Serrated polyposis: rapid and relentless development of colorectal neoplasia. [22490521] Gut 62(3):404-8 (2013)
PMC 288	Biomarkers in precision therapy in colorectal cancer. [24759962] Gastroenterol Rep (Oxf) 1(3):166-83 (2013)
PMC 289	Colorectal cancer in patients seen at the teaching hospitals of Guadeloupe and Martinique: discrepancies, similarities in clinicopathological features, and p53 status. [24679126] BMC Clin Pathol 14(1):12 (2014)
PMC 290	Colorectal cancer: prevention and management of metastatic disease. [24783222] Biomed Res Int 2014():782890 (2014)
PMC 291	Lynch syndrome from a surgeon perspective: retrospective study of clinical impact of mismatch repair protein expression analysis in colorectal cancer patients less than 50 years old. [24533633] BMC Surg 14():9 (2014)
PMC 292	The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. [22019796] Clin Gastroenterol Hepatol 10(3):272-7.e1 (2012)
PMC 293	Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. [23266556] Gastroenterology 144(4):799-807.e24 (2013)
PMC 294	Prognostic value of mandard and dworak tumor regression grading in rectal cancer: study of a single tertiary center. [24729903] ISRN Surg 2014():310542 (2014)
PMC 295	Future directions for the early detection of colorectal cancer recurrence. [24790655] J Cancer 5(4):272-80 (2014)
PMC 296	Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges. [24790654] J Cancer 5(4):262-71 (2014)
PMC 297	Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials. [24772337] J Gastrointest Oncol 5(2):99-103 (2014)
PMC 298	An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. [24674871] Oncologist 19(4):350-1 (2014)
PMC 299	Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. [23580238] Oncologist 18(4):377-8 (2013)
PMC 300	Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. [24922745] BMJ 348(): (2014)
PMC 301	Clinicopathological characteristics of laterally spreading colorectal tumor. [24751926] PLoS One 9(4):e94552 (2014)
PMC 302	Interval to surgery after neoadjuvant treatment for colorectal cancer. [24764663] World J Gastroenterol 20(15):4256-62 (2014)
PMC 303	Multimodal imaging evaluation in staging of rectal cancer. [24764662] World J Gastroenterol 20(15):4244-55 (2014)
PMC 304	Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. [24764661] World J Gastroenterol 20(15):4230-43 (2014)
PMC 305	Microscopic features of colorectal neoplasia in inflammatory bowel diseases. [24696602] World J Gastroenterol 20(12):3164-72 (2014)
PMC 306	Colonic and anal metastases from pancreato-biliary malignancies. [24707155] World J Gastroenterol 20(13):3693-7 (2014)
PMC 307	Evidence based medicine and surgical approaches for colon cancer: evidences, benefits and limitations of the laparoscopic vs open resection. [24707154] World J Gastroenterol 20(13):3680-92 (2014)
PMC 308	Transcription factor ERG is a specific and sensitive diagnostic marker for hepatic angiosarcoma. [24707153] World J Gastroenterol 20(13):3672-9 (2014)
PMC 309	Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. [24744578] World J Gastroenterol 20(14):3858-74 (2014)
PMC 310	Current and future molecular diagnostics in colorectal cancer and colorectal adenoma. [24744577] World J Gastroenterol 20(14):3847-57 (2014)
PMC 311	Role of preoperative CT colonography in patients with colorectal cancer. [24744573] World J Gastroenterol 20(14):3795-803 (2014)
PMC 312	Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. [24744571] World J Gastroenterol 20(14):3751-61 (2014)
PMC 313	Natural history of hepatic metastases from colorectal cancer--pathobiological pathways with clinical significance. [24744570] World J Gastroenterol 20(14):3719-37 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Colon and rectum (Neoplasia).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Colon and rectum (Neoplasia).php on line 92